MINT

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

MINT Accelerates US Growth with Key Appointments and New Partnerships, Welcoming Seasoned Strategist Federico Salvitti as VP of Growth

Retrieved on: 
onsdag, maj 8, 2024
Quotient, Strategic management, Thought, Partnership, ARM, MINT, Culture, Automation, IPO, IPSOS, Marketing, Advertising, Data management, Accenture, Female, Sales

Salvitti will report to MINT’s Chief Growth Officer Salvatore Internullo.

Key Points: 
  • Salvitti will report to MINT’s Chief Growth Officer Salvatore Internullo.
  • Salvitti serves as a professor at New York University, where he teaches Marketing Fundamentals, Data Management Strategy, and Business Strategy.
  • MINT has also made strategic appointments across its product, sales, marketing and customer success departments, further fortifying its growth efforts in the U.S. One of these key appointments is Mark D’Andrea, who has joined MINT’s US growth team.
  • “MINT is building a dynamic team, harnessing diverse expertise and talent to provide invaluable insight that fuels our growth and innovation in the US.

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, Risk, Poster, Disease, LNP, Cell, Sangamo Therapeutics, MINT, Publication, AAV, DNA, Patient, Gene, Society, Genome, Manuscript, BioRxiv, Modularity, Annual general meeting, Therapy, Vaccine

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
  • Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.
  • “Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field.
  • We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo.

PlatON Unveils State-of-the-art Web3 Payment Solutions at Money 20/20 Asia

Retrieved on: 
tisdag, april 23, 2024
Money, Fintech, Blockchain, MINT, Platon, Multimedia, Cryptocurrency

By converting deposits into blockchain-based tokens, deposit tokenization not only boosts asset liquidity but also offers more efficient and cost-effective solutions for cross-border payments and financial transactions.

Key Points: 
  • By converting deposits into blockchain-based tokens, deposit tokenization not only boosts asset liquidity but also offers more efficient and cost-effective solutions for cross-border payments and financial transactions.
  • At Money 20/20 Asia, PlatON showcased cutting-edge technology that not only demonstrates its expertise in the fintech sector but also signifies a significant step forward in driving payment technology innovation.
  • PlatON presented two payment methods, QRPAY and ZKPAY, as part of its on-chain payment acquiring solutions.
  • We've not only made strides in deposit tokenization technology but also demonstrated our on-chain payment solutions' capabilities in cross-border payments and payment clearing network construction.

TraceLink Named Finalist in the Prestigious Business Transformation & Operational Excellence Awards 2024

Retrieved on: 
måndag, april 22, 2024
Interoperability, PAI, Business transformation, Operational excellence, Once, MINT, Artificial intelligence, Patient, Organization, Management

BOSTON, April 22, 2024 /PRNewswire/ -- TraceLink, a global leader in integrated digital supply network solutions, is proud to announce its recognition as a finalist in the esteemed Business Transformation & Operational Excellence Awards 2024.

Key Points: 
  • BOSTON, April 22, 2024 /PRNewswire/ -- TraceLink, a global leader in integrated digital supply network solutions, is proud to announce its recognition as a finalist in the esteemed Business Transformation & Operational Excellence Awards 2024.
  • The Business Transformation & Operational Excellence Awards stand as the most prestigious recognition across industries, honoring organizations that have achieved significant success in transforming their operations and innovating at the highest levels.
  • "We are honored to be named finalists in the Business Transformation & Operational Excellence Awards 2024," said Shabbir Dahod, President and CEO of TraceLink.
  • The winners of the Business Transformation & Operational Excellence Awards 2024 will be announced at the upcoming awards ceremony on May 9th.

TraceLink Named Finalist in the Prestigious Business Transformation & Operational Excellence Awards 2024

Retrieved on: 
måndag, april 22, 2024
Interoperability, PAI, Business transformation, Operational excellence, Once, MINT, Artificial intelligence, Patient, Organization, Management

BOSTON, April 22, 2024 /PRNewswire/ -- TraceLink, a global leader in integrated digital supply network solutions, is proud to announce its recognition as a finalist in the esteemed Business Transformation & Operational Excellence Awards 2024.

Key Points: 
  • BOSTON, April 22, 2024 /PRNewswire/ -- TraceLink, a global leader in integrated digital supply network solutions, is proud to announce its recognition as a finalist in the esteemed Business Transformation & Operational Excellence Awards 2024.
  • The Business Transformation & Operational Excellence Awards stand as the most prestigious recognition across industries, honoring organizations that have achieved significant success in transforming their operations and innovating at the highest levels.
  • "We are honored to be named finalists in the Business Transformation & Operational Excellence Awards 2024," said Shabbir Dahod, President and CEO of TraceLink.
  • The winners of the Business Transformation & Operational Excellence Awards 2024 will be announced at the upcoming awards ceremony on May 9th.

Midwest Institute for Nonsurgical Therapy (MINT) Now Offers Innovative Treatment for Enlarged Prostate

Retrieved on: 
torsdag, april 18, 2024
Patient, Prostate, Risk, TURP, MINT, PAE, Medicare, Quality of life, BPH, Medical imaging

ST. LOUIS, April 18, 2024 /PRNewswire/ -- The Midwest Institute for Nonsurgical Therapy (MINT), a leading provider of minimally invasive medical procedures, is proud to announce the introduction of Prostate Artery Embolization (PAE) for the treatment of Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate.

Key Points: 
  • ST. LOUIS, April 18, 2024 /PRNewswire/ -- The Midwest Institute for Nonsurgical Therapy (MINT), a leading provider of minimally invasive medical procedures, is proud to announce the introduction of Prostate Artery Embolization (PAE) for the treatment of Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate.
  • "We are thrilled to offer Prostate Artery Embolization, a nonsurgical treatment that significantly improves the quality of life for patients suffering from BPH," said Dr. Akinwande.
  • MINT is among the few practices in the Midwest to offer this innovative service, positioning itself as a leader in nonsurgical therapies.
  • Patients seeking more information about Prostate Artery Embolization or to schedule a consultation can visit www.mintstl.com or contact MINT at 314 255 2204.

MINT Welcomes Shelley Zalis to Advisory Board

Retrieved on: 
torsdag, april 4, 2024
Quotient, Culture, Organization, IPSOS, Growth, Female, Intelligence, General partnership, Knowledge, Research, ARM, Fortune 500, MINT, Advertising, Management

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- MINT , the global enterprise software solution for advertising resource management (ARM), announced the addition of industry heavyweight Shelley Zalis , Founder and CEO of The Female Quotient to its advisory board.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- MINT , the global enterprise software solution for advertising resource management (ARM), announced the addition of industry heavyweight Shelley Zalis , Founder and CEO of The Female Quotient to its advisory board.
  • A research pioneer and well-known advocate for women’s equality, Zalis will provide strategic guidance and industry expertise for MINT.
  • Zalis is the newest addition to MINT’s expansive list of industry experts across its advisory board and board of directors, including Joe Zawadzki, General Partner at AperiamVentures, and known advertising expert.
  • “The addition of Shelley Zalis to MINT's advisory board marks a significant milestone in our journey towards driving digital transformation in advertising,” stated Lorenzo Larini, CEO of MINT.

ETHxCAT Launches: the Ultimate Cat-Themed Blockchain Game

Retrieved on: 
fredag, mars 22, 2024
Blockchain, Web3, Professional Services, Technology, Electronic Games, Fintech, Entertainment, NFT, Non-player character, Cat, MINT, Telegraphy, Cryptocurrency

It is built on Arbitrum chain, and it is an Ethscriptions empowered web3 game.

Key Points: 
  • It is built on Arbitrum chain, and it is an Ethscriptions empowered web3 game.
  • Designed to captivate cat lovers and blockchain enthusiasts alike, ETHxCAT stands out with its extensive selection of thousands of distinctively charming cats.
  • ETHxCAT unveils the new game model that intertwines strategy, adventure, and competition.
  • [ETHxCAT] is a pioneering force in the blockchain space, dedicated to creating innovative experiences for cat lovers worldwide.

TraceLink's 2023 Success: Expanded Digitalization Capabilities and Growing Adoption of New Supply Chain Solutions

Retrieved on: 
måndag, februari 5, 2024
Intelligence, PAI, Growth, Integration, DSCSA, MINT

These 1,600+ customers' supply chain activities operate in over 100 countries globally.

Key Points: 
  • These 1,600+ customers' supply chain activities operate in over 100 countries globally.
  • Solution Adoption: 50+ new clients in 2023 selected TraceLink's cutting-edge solutions in orchestration intelligence, partner orchestration, and process orchestration, demonstrating broad industry demand for end-to-end supply chain digitalization capabilities.
  • Supply Chain Work Management for Compliance Exceptions (SCWM): Facilitating the management and resolution of compliance exceptions efficiently, ensuring regulatory adherence while maintaining supply chain integrity.
  • Expanded DSCSA Capabilities: Streamlining compliance with the Drug Supply Chain Security Act (DSCSA), improving traceability and security in pharmaceutical supply chains while providing operational efficiency.